Alligator Bioscience AB (publ) (ATORX.ST)
SEK 6.18
(-1.89%)
SEK 6.18
(-1.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -248.58 Million SEK | -28.54% |
| 2022 | -193.39 Million SEK | -36.23% |
| 2021 | -141.96 Million SEK | 1.14% |
| 2020 | -143.6 Million SEK | 31.79% |
| 2019 | -210.53 Million SEK | -40.31% |
| 2018 | -150.04 Million SEK | -135.33% |
| 2017 | -63.75 Million SEK | -31.85% |
| 2016 | -48.35 Million SEK | -123.32% |
| 2015 | 207.37 Million SEK | 370.09% |
| 2014 | -76.78 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -49.21 Million SEK | 21.58% |
| 2024 Q3 | -66.51 Million SEK | -35.15% |
| 2024 Q1 | -62.75 Million SEK | 10.14% |
| 2023 Q3 | -52.5 Million SEK | 17.63% |
| 2023 Q2 | -63.73 Million SEK | -1.34% |
| 2023 FY | -248.58 Million SEK | -28.54% |
| 2023 Q1 | -62.89 Million SEK | -16.31% |
| 2023 Q4 | -69.83 Million SEK | -33.01% |
| 2022 Q1 | -43.12 Million SEK | -17.23% |
| 2022 FY | -193.39 Million SEK | -36.23% |
| 2022 Q4 | -54.07 Million SEK | -5.38% |
| 2022 Q3 | -51.31 Million SEK | -12.69% |
| 2022 Q2 | -45.53 Million SEK | -5.58% |
| 2021 FY | -141.96 Million SEK | 1.14% |
| 2021 Q2 | -34.95 Million SEK | -6.77% |
| 2021 Q3 | -37.24 Million SEK | -6.54% |
| 2021 Q4 | -36.79 Million SEK | 1.22% |
| 2021 Q1 | -32.74 Million SEK | 5.14% |
| 2020 Q2 | -35.05 Million SEK | 18.26% |
| 2020 Q3 | -30.84 Million SEK | 11.99% |
| 2020 FY | -143.6 Million SEK | 31.79% |
| 2020 Q4 | -34.51 Million SEK | -11.89% |
| 2020 Q1 | -42.88 Million SEK | 28.25% |
| 2019 Q2 | -49.3 Million SEK | -11.08% |
| 2019 FY | -210.53 Million SEK | -40.31% |
| 2019 Q4 | -59.76 Million SEK | -5.53% |
| 2019 Q3 | -56.63 Million SEK | -14.86% |
| 2019 Q1 | -44.38 Million SEK | -45.1% |
| 2018 Q3 | -39.63 Million SEK | -5.38% |
| 2018 Q4 | -30.58 Million SEK | 22.82% |
| 2018 Q1 | -42.2 Million SEK | -437.24% |
| 2018 FY | -150.04 Million SEK | -135.33% |
| 2018 Q2 | -37.61 Million SEK | 10.89% |
| 2017 Q3 | -25.77 Million SEK | 16.86% |
| 2017 FY | -63.75 Million SEK | -31.85% |
| 2017 Q1 | -19.5 Million SEK | -0.8% |
| 2017 Q2 | -31 Million SEK | -58.96% |
| 2017 Q4 | 12.51 Million SEK | 148.56% |
| 2016 Q2 | -45.06 Million SEK | -290.95% |
| 2016 Q1 | 23.59 Million SEK | 159.82% |
| 2016 FY | -48.35 Million SEK | -123.32% |
| 2016 Q4 | -19.34 Million SEK | -156.43% |
| 2016 Q3 | -7.54 Million SEK | 83.26% |
| 2015 FY | 207.37 Million SEK | 370.09% |
| 2015 Q3 | 278.57 Million SEK | 0.0% |
| 2015 Q4 | -39.45 Million SEK | -114.16% |
| 2014 FY | -76.78 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -1408.41% |
| Amniotics AB (publ) | -30.87 Million SEK | -705.267% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1837.839% |
| BioArctic AB (publ) | 229.24 Million SEK | 208.435% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 46.677% |
| Genovis AB (publ.) | 61.5 Million SEK | 504.205% |
| LIDDS AB (publ) | -40.2 Million SEK | -518.281% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2142.781% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1463.237% |
| Saniona AB (publ) | -95.81 Million SEK | -159.457% |
| Simris Alg AB (publ) | -37.3 Million SEK | -566.361% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 20.054% |
| AcouSort AB (publ) | -17.08 Million SEK | -1354.655% |
| Active Biotech AB (publ) | -45.8 Million SEK | -442.764% |
| Camurus AB (publ) | 431.44 Million SEK | 157.617% |
| Cantargia AB (publ) | -280.02 Million SEK | 11.228% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1078.635% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -119.361% |
| Mendus AB (publ) | -101.61 Million SEK | -144.626% |
| Kancera AB (publ) | -64.88 Million SEK | -283.094% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 4715.41% |
| Lipum AB (publ) | -37.17 Million SEK | -568.637% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1949.687% |
| NextCell Pharma AB | -41.95 Million SEK | -492.438% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 35.96% |
| Xintela AB (publ) | -54.08 Million SEK | -359.638% |
| Ziccum AB (publ) | -21.41 Million SEK | -1060.966% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1415.955% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1288.981% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -570.567% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -38.359% |
| CombiGene AB (publ) | -35.66 Million SEK | -596.995% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -63.705% |
| Intervacc AB (publ) | -102.85 Million SEK | -141.693% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -56654.795% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1404.485% |
| Corline Biomedical AB | -1.8 Million SEK | -13641.625% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -39.781% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -337.49% |
| Aptahem AB (publ) | -11.11 Million SEK | -2136.92% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -101.991% |
| Fluicell AB (publ) | -26.55 Million SEK | -836.153% |
| Biovica International AB (publ) | -124.82 Million SEK | -99.151% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -488.745% |
| Abliva AB (publ) | -95.5 Million SEK | -160.275% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 23.957% |
| 2cureX AB (publ) | -32.51 Million SEK | -664.457% |
| I-Tech AB | 20.2 Million SEK | 1330.441% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 70.112% |
| Cyxone AB (publ) | -22.98 Million SEK | -981.326% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -171.973% |
| Biosergen AB | -27.03 Million SEK | -819.429% |
| Nanologica AB (publ) | -75.15 Million SEK | -230.756% |
| SynAct Pharma AB | -215.81 Million SEK | -15.187% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -464.276% |
| BioInvent International AB (publ) | -330.3 Million SEK | 24.74% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -947.251% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 0.211% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -2403.381% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -127.46% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2028.669% |